Clinical trials
HIV Infection Primary clinical trials
Below are recruiting hiv infection primary clinical trials, each written for real people, not researchers. We’re tracking 35 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06872307Recruiting
Helping Black men stay on PrEP
This study tests a new way to help Black men who have sex with men stay on PrEP (HIV prevention pills) over time. If you are at risk for HIV and have stopped taking PrEP for at least a month, you may be able to join and get support to keep taking it.
Washington D.C., District of ColumbiaAges 18 years+ - NCT05492565Enrolling by invitation
Follow-up study for people on HIV prevention pills
This study follows adults who are at high risk of getting HIV while they take HIV prevention pills (PrEP). It aims to learn how well PrEP fits real-life use in people at risk and who may need extra care.
Seville, AndalusiaAges 18 years+ - NCT04160455Recruiting
Study of GALIG proteins in adults with HIV on or off treatment
This study looks at how “GALIG” gene products affect the body’s internal recycling process (called autophagy) in people living with HIV. It may help researchers understand differences between people on HIV treatment, starting treatment, or not currently taking it.
OrléansAges 18 years+ - NCT06203132RecruitingPhase 3
Doravirine vs Dolutegravir for first-time HIV treatment
This study compares two HIV medicines, doravirine and dolutegravir, to see which works better for people who have never taken HIV treatment before. If you qualify, you would be randomly assigned to one of the two medications.
Nova Iguaçu, Rio de JaneiroAges 18 years+ - NCT06266416Recruiting
Black caregivers & girls empowerment study
This study tests a program called IMARA to support black male caregivers and the girls they care for. It aims to improve family relationships and reduce risky behaviors in girls.
Chicago, IllinoisAges 13 years+ - NCT04663152Recruiting
Study support to help you stay on treatment
This study tests integrated support that includes counseling, help with following your treatment plan, and research activities to improve treatment adherence. You may be a good match if you live in Miami-Dade and meet the viral load requirement.
Miami, FloridaAges 18 years+ - NCT05300035RecruitingPhase 2
HIV treatment add-on antibodies during early infection
This study tests whether adding two antibody medicines to standard HIV treatment helps people control HIV better after stopping treatment. It focuses on people with recently diagnosed (“primary”) HIV infection, aiming to improve long-term control after ART is interrupted.
BobignyAges 18–70 - NCT06659952Recruiting
HIV+ donor hearts for HIV+ recipients
This trial tests whether hearts from donors who had HIV can be safely transplanted into people with HIV who need a heart transplant. It may offer a new option for those on the waiting list.
Dallas, TexasAges 18 years+ - NCT00006518Recruiting
Tissue samples from people with viral infections or cancer
This study collects tissue and blood samples from people who have or have been exposed to certain viruses (HIV, KSHV, HPV, EBV, or HTLV-1) or who have developed cancer or precancerous skin lesions. The samples help researchers understand how these viruses may lead to cancer.
Bethesda, MarylandAges 18–120 - NCT00789009Recruiting
Monitoring people with known or suspected HIV infection
This study tests how well researchers can track HIV-related health and immune changes over time by collecting blood and other samples. It may help you and your care team by creating detailed monitoring, even if your HIV diagnosis is new or still being evaluated.
Bethesda, MarylandAges 18 years+ - NCT05078957Recruiting
Study gut microbiome in older adults with well-controlled HIV
This trial studies how the bacteria in your gut (“microbiome”) relate to frailty (weakness/low physical resilience) in people with HIV who are stably doing well on treatment. It may help researchers understand why some people become frail and how the gut may play a role.
MarseilleAges 55 years+ - NCT06013579Recruiting
Exercise study for older adults with HIV
This study tests whether high-intensity exercise can help improve thinking and memory, and build lasting exercise habits, in older adults living with HIV who feel tired and are not very active.
Birmingham, AlabamaAges 50–80 - NCT07473778Recruiting
Study of Lenacapavir for HIV Prevention
This trial tests a new medication, lenacapavir, to see how well it works for preventing HIV. It is for people who want or need PrEP (a medicine to prevent HIV) and are interested in learning about different options.
Birmingham, AlabamaAges 18 years+ - NCT01222741Recruiting
Study of people with higher risk of fungal infections
This study looks at immune system differences that can make some people get unusual or frequent fungal (fungus) infections. It may help researchers better understand these conditions, and you may be asked to store blood for future research.
Bethesda, MarylandAges 18–85 - NCT04174755Recruiting
Semaglutide for weight loss in adults with HIV
This trial studies whether semaglutide (a diabetes-type weight-loss injection) helps adults with HIV lose weight. It also checks that it’s safe for people whose HIV is well controlled on regular treatment.
Dublin, DublinAges 18 years+ - NCT06886971Recruiting
Strategies to help youth with HIV stay virally suppressed
This trial tests a strategy to help young people with HIV keep their virus levels low. It focuses on using a long-acting injectable medication combination (Cabotegravir and Rilpivirine) and requires communication with your HIV doctor.
Baltimore, MarylandAges 12–30 - NCT07477925Recruiting
Studying immune markers for CMV in pregnancy
This study looks at how the immune system responds to a first-time cytomegalovirus (CMV) infection during pregnancy. The goal is to find better ways to predict if the virus will pass to the baby.
Pavia, LombardyAges 18 years+ - NCT07650916RecruitingPhase 3
A study of two ultra-long-acting HIV shots
This trial tests a new ultra-long-acting injectable combination of cabotegravir and rilpivirine for people with HIV who already have the virus under control. It aims to see if these shots can keep the virus suppressed with fewer doses.
Phoenix, ArizonaAges 12 years+ - NCT03266653RecruitingPhase 2
T-cell therapy for stubborn Epstein-Barr virus after transplants
This trial tests an immune therapy made from EBV-targeted T-cells to treat EBV infections that do not improve with standard anti-viral medicines. It may help by strengthening the body’s ability to fight EBV after certain transplants or immune problems.
Los Angeles, CaliforniaAges 1 month–79 years - NCT07261969Recruiting
Blood test and leaflet to guide antibiotic use for respiratory infections
This trial tests if a quick blood test (C-reactive protein, CRP) and a patient leaflet can help doctors prescribe antibiotics only when needed for adults with respiratory tract infections. It aims to reduce unnecessary antibiotic use.
Sokuluk Village, Chui RegionAges 18–70 - NCT05943548Recruiting
Traditional healer support to help HIV reach low viral levels
This study tests whether support from traditional healers can help people with HIV get their viral load down to very low levels. You may be offered additional support and asked to attend clinic and nurse visits over 2 years.
MbararaAges 18 years+ - NCT04197596RecruitingPhase 1/Phase 2
BK infection immune-cell treatment after transplant or weak immunity
This Phase 1/2 study tests lab-made immune cells that specifically target BK virus in people whose BK infection keeps coming back or doesn’t improve. It may help by boosting the body’s ability to clear the virus, especially when standard antiviral treatments don’t work or can’t be tolerated.
San Francisco, CaliforniaAges 1 month–79 years - NCT04851015RecruitingPhase 3
Low-dose TMP-SMX for Pneumocystis pneumonia (PCP)
This Phase 3 study tests whether low-dose trimethoprim-sulfamethoxazole (also called TMP-SMX) can treat Pneumocystis pneumonia (PCP) in people with weakened immune systems. It may help improve treatment while reducing side effects compared with standard dosing.
Montreal, QuebecAges 18–100 - NCT05077527RecruitingPhase 1
CAR-T treatment for HIV and aggressive B-cell lymphoma
This trial studies a lab-made immune cell treatment (CAR-T) for adults who have HIV and aggressive B-cell non-Hodgkin lymphoma that has come back or did not respond to prior treatment. It aims to see if the treatment can control the lymphoma safely in this specific group.
Duarte, CaliforniaAges 18 years+
Hear when a new HIV Infection Primary trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for hiv infection primary?
- Yes. Clin2 currently lists 35 recruiting hiv infection primary studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a hiv infection primary trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a hiv infection primary trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.